Tirzepatide 15 mg produced 5.5 kg more weight loss than semaglutide 1 mg (p 25,000 participants in the SURPASS and SURMOUNT programs [1, 2, 3]: Gastrointestinal effects (most common, dose-dependent): Nausea: 12-18% (5 mg), 15-22% (10 mg), 18-28% (15 mg) vs
In some studies, the same NPI will be used for all participants, while personalized risk-reduction trials may tailor interventions to the specific risks and preferences of each participant (Yaffe et al., 2024)
doi: 10.1016/S0140-6736(03)14370-X 148 ThompsonTButlerMGMacLeanWEJosephB
10.1038/s41580-020-00324-8 47 JiangY
Participants were assigned to one of two treatment orderseither placebo in the first session followed by naltrexone in the second or vice versausing an online randomization system provided by the Kings Clinical Trials Unit